Friday, 19 Oct 2018

You are here

An Association between GCA and IBD ?

A population based analysis from Israel suggests that giant cell arteritis (GCA) patients may be at increased risk for  inflammatory bowel diseases (IBD) mainly target.

This research was based on sporadic reports in the medical literature (http://bit.ly/2pnIPM0)

Claims data analysis of 3938 GCA patients and 21,623 matched controls finds that  GCA patients had a significantly increased rates of CD and UC (0.79% vs. 0.12% and 0.84% vs. 0.21%, P-value < .001, respectively) when compared to normal controls.

This GCA and IBD association was negatively correlated with the patients' age; and was more robust in middle-aged (OR = 8.13) than in elderly patients (OR = 3.81).

Such data should influence the medical and GI evaluations of GCA patients suffering from gastrointestinal complaints, especially in middle-aged patients (50-69 years of age).  Moreover, age related routine colonoscopy should be strongly encouraged in such GCA patients.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

The GI literature is growing with the suggestion that IL-6 is the next cytokine in Crohn's Disease. The question I have had to come to terms with is when it is seen in younger patients < 40 yo) and whether this is Takayasu's or Aortitis unique to CD. As such is this an extra-intestinal manifestation that might parallel the bowel (e.g. Type I Peripheral arthritis) or march on independent of the bowel (e.g spondylitis).
IL-6 is a potential new target but there is really very little published data on IL-6 inhibition in IBD patients. Whether large vessels vasculitis could be considered an extraintestinal manifestation is interesting but best left to an IBD expert to address - Ill see if I can get one to address this for you, me and the RheumNow audience. Thanks for these thoughtful comments. JC

More Like This

Teenage Obesity Increases Lupus Risk

Analysis of the Black Women's Health Study shows that obesity as a teenager may be associated with increased risk of systemic lupus erythematous (SLE) in adulthood.

The relationship between obesity and SLE risk is unclear. Past studies have predominantly assessed white women, while black women have higher prevalence of both obesity and SLE.

SLE-Scleroderma Overlap Outcomes

Overlap of autoimmune disorders represents a significant diagnostic and management challenge to the rheumatologist. A novel cohort analysis of overlap between systemic sclerosis (SSc) and systemic lupus erythematous (SLE) suggests such patients tend to be younger, more frequently have PAH, but less cutaneous manifestations of SSc.

Excess Mortality in CTD or Systemic Vasculitis Patients

The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.

Mortality Improves in Lupus ESRD

The past two decades have seen a significant decline in mortality among patients with lupus nephritis, U.S. registry data indicated.

Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.